Previous Close | 0.5450 |
Open | 0.5450 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.5450 - 0.5450 |
52 Week Range | 0.5450 - 2.6000 |
Volume | |
Avg. Volume | 1 |
Market Cap | 21.038M |
Beta (5Y Monthly) | 1.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1700 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LYON, France, February 15, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2023.
LYON, France, January 03, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.
LYON, France, December 21, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, provides a corporate update.